Pages that link to "Q39086041"
Jump to navigation
Jump to search
The following pages link to Influence of adjuvants on the antibody specificity to the Plasmodium falciparum major merozoite surface protein, gp195. (Q39086041):
Displaying 17 items.
- Generation of humoral immune responses to multi-allele PfAMA1 vaccines; effect of adjuvant and number of component alleles on the breadth of response (Q28748610) (← links)
- Characterization of protective epitopes in a highly conserved Plasmodium falciparum antigenic protein containing repeats of acidic and basic residues. (Q33755404) (← links)
- Pathways for potentiation of immunogenicity during adjuvant-assisted immunizations with Plasmodium falciparum major merozoite surface protein 1. (Q33767686) (← links)
- Partial protection against Plasmodium vivax blood-stage infection in Saimiri monkeys by immunization with a recombinant C-terminal fragment of merozoite surface protein 1 in block copolymer adjuvant (Q34000050) (← links)
- Characterization of conserved T- and B-cell epitopes in plasmodium falciparum major merozoite surface protein 1 (Q34004267) (← links)
- Mechanisms of monophosphoryl lipid A augmentation of host responses to recombinant HagB from Porphyromonas gingivalis (Q34126807) (← links)
- The development and use of vaccine adjuvants (Q34680503) (← links)
- Influence of adjuvants on protection induced by a recombinant fusion protein against malarial infection (Q35504908) (← links)
- Plasmodium falciparum: immunization with MSP1-42 induced non-inhibitory antibodies that have no blocking activities but enhanced the potency of inhibitory anti-MSP1-42 antibodies (Q35762375) (← links)
- Adjuvant-dependent immune response to malarial transmission-blocking vaccine candidate antigens (Q36231958) (← links)
- The requirement of CD80, CD86, and ICAM-1 on the ability of adjuvant formulations to potentiate antibody responses to a Plasmodium falciparum blood-stage vaccine (Q36398927) (← links)
- Interleukin-6 has differential influence on the ability of adjuvant formulations to potentiate antibody responses to a Plasmodium falciparum blood-stage vaccine (Q36484748) (← links)
- Iron oxide nanoparticles as a clinically acceptable delivery platform for a recombinant blood-stage human malaria vaccine (Q36615170) (← links)
- Adjuvant formulations possess differing efficacy in the potentiation of antibody and cell mediated responses to a human malaria vaccine under selective immune genes knockout environment (Q36766169) (← links)
- Roles of conserved and allelic regions of the major merozoite surface protein (gp195) in immunity against Plasmodium falciparum (Q36943106) (← links)
- Regulation of CD4 T-cell receptor diversity by vaccine adjuvants (Q37717709) (← links)
- Biological activities of anti-merozoite surface protein-1 antibodies induced by adjuvant-assisted immunizations in mice with different immune gene knockouts (Q39085980) (← links)